Yale Study Explores GLP-1 Medicines for Weight Management in Type 1 Diabetes

Living with type 1 diabetes is complex. Adding obesity to the picture makes it even more so. Research shows that more than 40% of young adults with type 1 diabetes also experience overweight or obesity. Despite how common this combination is, there is limited research into treatments that address both conditions together.

This is where a new Yale University trial comes in. Researchers are testing whether a GLP-1 analogue—a class of medicines that has shown heart-protective benefits in people with type 2 diabetes—might help young adults who have both type 1 diabetes and obesity.

Most research on GLP-1 medicines in type 1 diabetes has focused on blood sugar control. This Yale trial takes a different approach. The study's main goals are to measure changes in abdominal fat distribution, hepatic insulin resistance (how well the liver responds to insulin), and triglycerides—all key markers tied to heart health and metabolic health.

The trial plans to enroll 54 young adults with both type 1 diabetes and obesity. Researchers will collect data over 12 months to see whether the GLP-1 analogue offers benefits beyond blood sugar management.

It's important to be clear: GLP-1 medicines are not approved for type 1 diabetes, and they do not replace insulin. This is an early-stage research study—a phase 2 trial—which means results are still being gathered and no conclusions have been published yet.

The trial reflects a growing interest in understanding how medicines developed for type 2 diabetes might be adapted or studied differently for people with type 1 diabetes, especially those facing the added challenge of obesity. But research takes time, and findings from this trial will need to be carefully reviewed before any new treatment approaches become available.

Yale University is actively recruiting participants for this trial. If you have type 1 diabetes, obesity, and are interested in participating in clinical research, you can find more information on ClinicalTrials.gov using the trial identifier NCT06411210.

As always, any questions about your own treatment should be discussed with your diabetes care team. This article reports on research in progress and is not medical advice.

Origin: T1D Pulse (Video report). Evidence: Video report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.